Formulation having mobilising activity
US8771663B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Apr 6, 2010 |
| Grant date | Jul 8, 2014 |
| Priority date | — |
| Expiry date | Mar 27, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P7/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.